rethinkTHC Search
Menu
Study breakdown

Cannabinoid Treatment Reduced Alzheimer's Plaques and Improved Memory in Mice

Animal StudyPreliminary evidence
The takeaway

Ninety days of intermittent cannabinoid treatment in an Alzheimer's mouse model reduced anxiety, partially reversed cognitive deficits, decreased amyloid plaque deposits, and lowered brain glucose metabolism.

Alzheimer's researchers, neurologists, and those interested in cannabinoid neuroprotection

Reduced amyloid plaque number and size after 90-day treatment

What the researchers found

Chronic treatment with JWH-133 (a selective CB2 agonist) and Cannabis sativa extract reduced anxiety-like behavior and partially reversed recognition memory deficits in APP/PS1 mice. Both treatments reduced the number and size of amyloid-beta plaque deposits, decreased cerebral glucose metabolism, reduced mTOR and CB2 receptor expression, and enhanced M1 muscarinic acetylcholine receptor expression.

Why it matters

Alzheimer's disease has no effective treatment despite decades of research. The finding that cannabinoid receptor ligands can reduce plaque deposits and improve cognition in an Alzheimer's model, through the expanded endocannabinoid system, opens a new therapeutic avenue worth pursuing.

The numbers in context

Treatment: 90 days intermittent. JWH-133: 0.2 mg/kg. Cannabis extract: 2.5 mg/kg. Outcomes: reduced anxiety, partially reversed cognitive deficits, reduced amyloid-beta plaque number and size, decreased cerebral glucose metabolism, reduced mTOR and CB2 expression, increased M1 mAChR expression.

How the study worked

APP/PS1 transgenic mice (Alzheimer's model) received 90 days of intermittent treatment with JWH-133 (0.2 mg/kg) or EU-GMP certified Cannabis sativa (Cannabixir Medium Flos, 2.5 mg/kg). Recognition memory, anxiety behavior, brain imaging, and molecular markers were assessed.

What this study cannot tell us

Mouse model findings often do not translate to human Alzheimer's. APP/PS1 mice only model the amyloid component of Alzheimer's, not the full disease. The treatment regimen (90 days intermittent) may not represent practical clinical dosing. No long-term follow-up.

How to read the evidence

Well-designed preclinical study with multiple outcome measures, but animal model findings require human validation.

When this study was published

2024 study

The bigger picture

The endocannabinoid system is increasingly recognized as a modulator of neuroinflammation and neurodegeneration. That both a selective CB2 agonist and a full cannabis extract showed similar benefits suggests the CB2 receptor pathway may be a key therapeutic target for Alzheimer's.

Questions still open

  • Would CB2-selective agonists work in humans with Alzheimer's? Can cannabinoid treatment halt or just slow plaque accumulation? What is the role of the mTOR pathway reduction in the observed benefits?

Common questions

Could cannabinoids help with Alzheimer's disease?
In this mouse study, cannabinoid treatment reduced Alzheimer's-associated brain plaques, improved memory, and reduced anxiety over 90 days. Human clinical trials are needed before drawing conclusions.
Which cannabinoid receptors are involved in Alzheimer's?
This study found that both a selective CB2 receptor agonist and whole cannabis extract produced similar benefits, suggesting the CB2 receptor pathway is a key target for Alzheimer's-related neuroinflammation.

Read the original research

Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer's Disease Treatment.

Pharmaceuticals (Basel, Switzerland), 17(4)

Citation

Stanciu, Gabriela Dumitrita; Ababei, Daniela-Carmen; Solcan, Carmen; Uritu, Cristina-Mariana; Craciun, Vlad-Constantin; Pricope, Cosmin-Vasilica; Szilagyi, Andrei; Tamba, Bogdan-Ionel. (2024). Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer's Disease Treatment.. Pharmaceuticals (Basel, Switzerland), 17(4). https://doi.org/10.3390/ph17040530

Explore the wider topic